PA
GSK icon

Probity Advisors’s GSK GSK Stock Holding History

Probity Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Sell
24,377
-75
-0.3% -$3.97K 0.18% 87
2026
Q1 		$1.35M Sell
24,452
-323
-1% -$17.5K 0.21% 84
2025
Q4 		$1.21M Sell
24,775
-676
-3% -$31.5K 0.19% 84
2025
Q3 		$1.1M Buy
25,451
+1,766
+7% +$69K 0.18% 90
2025
Q2 		$910K Buy
23,685
+4,484
+23% +$171K 0.16% 98
2025
Q1 		$744K Buy
19,201
+4,081
+27% +$149K 0.14% 112
2024
Q4 		$511K Buy
15,120
+5,599
+59% +$202K 0.1% 140
2024
Q3 		$389K Sell
9,521
-119
-1% -$4.87K 0.07% 176
2024
Q2 		$371K Buy
9,640
+460
+5% +$19.4K 0.08% 171
2024
Q1 		$394K Sell
9,180
-759
-8% -$31.3K 0.08% 165
2023
Q4 		$368K Buy
9,939
+2,084
+27% +$74.8K 0.08% 162
2023
Q3 		$285K Buy
7,855
+2,168
+38% +$76.9K 0.07% 157
2023
Q2 		$203K Buy
+5,687
New +$204K 0.04% 185

Other funds holding GSK

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
MHI
Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Probity Advisors's GSK Position: Q2 2026 in Review

Probity Advisors reduced its GSK (GSK) stake by 0.31% in Q2 2026, selling an estimated $3.97K and leaving 24,377 shares worth $1.28M. The position accounts for 0.18% of the portfolio, ranked #87.

Probity Advisors first reported a position in GSK in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.35M in Q1 2026. 505 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Probity Advisors held 24,377 shares of GSK worth $1.28M as of Q2 2026.
  • Probity Advisors sold 75 GSK shares in Q2 2026, an estimated $3.97K.
  • GSK made up 0.18% of Probity Advisors's portfolio in Q2 2026, its #87 holding.
  • Probity Advisors first reported a position in GSK in Q2 2023 and has held it in 13 quarters since.
  • Probity Advisors's GSK position peaked at $1.35M in Q1 2026.
  • 505 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.